Snapshot img

Bipolar Disorder Therapeutics Market Size 2024-2028

The bipolar disorder therapeutics market size is forecast to increase by USD 787.02 million at a CAGR of 2.68% between 2023 and 2028. The market is experiencing significant growth due to the rising incidence of this mental health condition. According to the National Institute of Mental Health, approximately 2.8% of adults in the United States have bipolar disorder. The market is driven by the development of innovative treatments, including tricyclic antidepressant drugs, beta blockers, anti-psychotic drugs, lithium (Li) element, vasopressin hormone, and anticonvulsant drugs. These medications help manage the symptoms of bipolar disorder, which include extreme mood swings between mania and depression. Another trend in the market is the increasing prevalence of personalized treatment approaches due to advances in genetics and neuroscience. Lithium works by stabilizing the mood by regulating the activity of certain chemicals in the brain. This personalization allows for more effective treatment plans tailored to individual patients, leading to better outcomes. However, the stigma surrounding mental health issues remains a challenge, hindering diagnosis and treatment. The market is expected to continue growing as research and development efforts continue to uncover new treatment options and improve existing ones.

Request Free Sample

Bipolar disorder, also known as manic-depressive illness, is a mental health condition characterized by extreme mood swings between mania and depression. According to the National Institute of Mental Health, approximately 2.8% of adults in the US are affected by this disorder. The need for effective therapeutic options to manage the symptoms of bipolar disorder is a significant concern for medical institutions, scientific organizations, and government entities. Government efforts have been instrumental in funding research and development of new therapeutics for bipolar disorder. For instance, the National Institute of Mental Health (NIMH) has been investing in studies to explore the underlying causes of bipolar disorder and identify potential treatments.

Moreover, medical institutions and scientific organizations are focusing on developing various classes of drugs to manage the symptoms of bipolar disorder. These include mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, and anti-anxiety drugs. Mood stabilizers, such as lithium (Li) element and valproate, are commonly used to treat bipolar disorder. Lithium, a naturally occurring element, has been in use since the 1940s and is considered the gold standard for treating bipolar I disorder. Anticonvulsant drugs, such as carbamazepine, valproate, and lamotrigine, are also used to manage the symptoms of bipolar disorder.

Additionally, these drugs are primarily used to treat epilepsy but have been found to be effective in stabilizing mood in individuals with bipolar disorder. Antipsychotic drugs, such as cariprazine, aripiprazole, olanzapine, and lurasidone, are used to manage the manic and psychotic symptoms of bipolar disorder. These drugs work by blocking the dopamine and serotonin receptors in the brain, helping to reduce the symptoms of mania and psychosis. Antidepressant drugs, such as tricyclic antidepressant drugs and selective serotonin reuptake inhibitors (SSRIs), are used to treat the depressive symptoms of bipolar disorder. However, these drugs can increase the risk of manic episodes and are typically used in combination with mood stabilizers.

Also, beta blockers, such as propranolol, are sometimes used off-label to manage the symptoms of mania and agitation in individuals with bipolar disorder. These drugs work by blocking the action of adrenaline, a hormone that can contribute to manic symptoms. The route of administration of these drugs can vary, with oral administration being the most common. However, parenteral administration, such as intramuscular or intravenous, may be necessary in certain situations, such as during manic episodes or hospitalization. Scientific organizations are also exploring alternative approaches to treating bipolar disorder, such as the use of vasopressin hormone and diabetes insipidus.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Drug Class

  Antipsychotics
  Mood stabilizers
  Antidepressants
  Others


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Drug Class Insights

The antipsychotics segment is estimated to witness significant growth during the forecast peri

The global bipolar disorder market is projected to be valued at $9.7 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 3.2%, reaching approximately $13.5 billion by 2034.

Bipolar Disorder Therapeutics Market Outlook

The global Bipolar Disorder Therapeutics Market is poised for significant growth, with a market size valued at approximately USD 5.8 billion in 2023. By 2032, the market is projected to reach USD 9.7 billion, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth is driven by increasing awareness and understanding of bipolar disorder, advancements in treatment methodologies, and a rise in the prevalence of the condition worldwide. The growing need for innovative and effective therapies to manage the disorder is propelling the market forward, along with a supportive regulatory environment encouraging the development of new treatments.

One of the primary growth factors influencing this market is the increasing prevalence of bipolar disorder globally. As mental health awareness continues to rise, more individuals are seeking diagnosis and treatment, thereby expanding the patient pool that requires therapeutic interventions. Additionally, improvements in diagnostic techniques have led to earlier and more accurate identification of bipolar disorder, facilitating timely interventions and management plans. This growing demand for effective treatments is expected to fuel the market for bipolar disorder therapeutics in the coming years. Furthermore, the societal shift towards prioritizing mental health and reducing stigma around mental illness is encouraging individuals to seek professional help, thereby increasing the market demand for therapeutics.

Continued research and development in pharmacological therapies are also playing a crucial role in the expansion of the Bipolar Disorder Therapeutics Market. Pharmaceutical companies are investing heavily in developing new drug formulations and combinations aimed at better managing the symptoms of bipolar disorder with fewer side effects. The advent of personalized medicine and the integration of novel drug delivery systems, such as long-acting injectables, are further enhancing treatment outcomes. These advancements not only improve patient compliance and quality of life but also broaden the scope of therapeutic options available to healthcare providers, driving market growth.

Another significant growth driver is the increasing acceptance and incorporation of non-pharmacological treatments alongside traditional pharmacological therapies. Evidence-based psychological interventions, such as cognitive-behavioral therapy (CBT), psychoeducation, and family-focused therapy, are gaining traction as essential components of comprehensive treatment plans. Healthcare providers are increasingly adopting a holistic approach to bipolar disorder management, which includes lifestyle modifications, therapy sessions, and pharmacological treatments. This integration of diverse treatment modalities is expected to bolster market growth as it offers patients a more personalized and effective approach to managing their condition.

From a regional perspective, North America remains a dominant force in the Bipolar Disorder Therapeutics Market, driven by a well-established healthcare infrastructure, high awareness levels, and favorable reimbursement policies. The region is home to several key market players and research institutions actively involved in developing innovative bipolar disorder treatments. Asia Pacific, on the other hand, is anticipated to witness the fastest growth during the forecast period. Factors such as a large patient population, increasing healthcare expenditure, and growing awareness about mental health disorders are driving market expansion in this region. Meanwhile, Europe continues to be a significant market due to robust healthcare systems and substantial investments in mental health research and development.

Antimania Drugs have become a cornerstone in the treatment of manic episodes associated with bipolar disorder. These medications are specifically designed to stabilize mood and reduce the intensity of manic symptoms, providing relief for patients experiencing heightened energy levels, irritability, and impulsivity. The development of Antimania Drugs has evolved over the years, with pharmaceutical companies focusing on enhancing their efficacy while minimizing side effects. This focus on improving the therapeutic profile of Antimania Drugs is crucial, as it allows patients to maintain a balanced mood without experiencing significant adverse effects. As research continues, new formulations and drug combinations are being explored to offer more targeted and effective management of mania, contributing to the overall growth of the b

The Bipolar Disorder Therapeutic market is a vital segment of the global healthcare industry, focusing on the treatment of bipolar disorder, a mental health condition characterized by extreme mood swings, including emotional highs (mania or hypomania) and lows (depression). This market encompasses a range of pharmac

Global Bipolar Disorder Drugs and Treatment Market is segmented by Application (Mania control_Depression relief_Mixed episodes_Maintenance therapy_Suicide prevention), Type (Antipsychotics_Mood stabilizers_Antidepressants_CBT_ECT), and Geography (North America_ LATAM_ West Europe_Central & Eastern Europe_ Northern Europe_ Southern Europe_ East Asia_ Southeast Asia_ South Asia_ Central Asia_ Oceania_ MEA)

Get key insights on Market Research Intellect's Bipolar Disorder Drugs Market Report: valued at USD 5.67 billion in 2024, set to grow steadily to USD 8.12 billion by 2033, recording a CAGR of 4.8%.Examine opportunities driven by end-user demand, R&D progress, and competitive strategies.

The Antimania Drugs market plays a crucial role in the healthcare industry, particularly in the management and treatment of various anxiety disorders and mood disturbances. These pharmaceutical solutions are designed to alleviate symptoms associated with mania, providing essential support to those affected by condit

Context:

"Tulip mania, tulipmania, or tulipomania (Dutch names include: tulpenmanie, tulpomanie, tulpenwoede, tulpengekte and bollengekte) was a period in the Dutch Golden Age during which contract prices for bulbs of the recently introduced tulip reached extraordinarily high levels and then dramatically collapsed in February 1637. It is generally considered the first recorded speculative bubble (or economic bubble)." -- From Wikipedia, CC BY-SA

Market forecasting is difficult. There are many factors that may affect the market, and a high degree of uncertainty. One thing that some researchers have been investigating is whether natural language processing (NLP) of news texts can help with market forecasting. Recent publications suggest that it can be.

• Peng, Y., & Jiang, H. (2016). Leverage Financial News to Predict Stock Price Movements Using Word Embeddings and Deep Neural Networks. In Proceedings of NAACL-HLT (pp. 374-379).
• Fraiberger, S. P. (2016). News Sentiment and Cross-Country Fluctuations. NLP+ CSS 2016, 125.

This dataset an interesting test case for these methodologies. It contains Dutch-language newspapers from the years immediately preceding and following tulip mania. Can you use NLP techniques to model the tulip market over time?

Content:

This dataset contains the texts of 8,559 newspaper deliveries from the 17th century, from June 14th, 1618 to December 31, 1699. The text is in Dutch. Since the text was scraped from old newspapers using OCR (optical character recognition), there are some errors in the text.

Acknowledgments:

This dataset was compiled by Delpher, an archive service provided by the National Library of the Netherlands. It is provided under a CC-BY 4.0 license. For more information, and newspapers from other years, please visit their website (in Dutch). If you use this dataset in your work, please include this citation:

Delpher open newspaper archive (1.0). Creative Commons Attribution 4.0 , The Hague, 2017 .

In Japan Machine Vision Camera Market, Manic will aid in the development in a quick time at a reasonable cost because it offers example designs of hardware and software.

Snapshot img { margin: 10px !important; } Overview of the drug development pipeline for bipolar disorder

Bipolar disorder is also known as manic depression that causes extreme shifts in mood, energy, and activity levels. Elevated mood swings are called mania or hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized into bipolar I, bipolar II, and cyclothymia. This condition can be managed with a regular treatment. Insomnia, weight gain or loss, behavioral changes, and psychological imbalances are some of the symptoms witnessed in individuals with bipolar disorder. Technavio’s market research analysts have predicted that with the introduction of behavioral therapy, substance abuse treatment, and electroconvulsive therapy as some of the most promising approaches to treat bipolar disorder, the global bipolar disorder market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase III, pre-clinical, discover drug development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase I, phase II, and phase II/III development stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of bipolar disorder. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

Amorsa Therapeutics
KemPharm
NeuroRx

Therapeutic assessment of the drug development pipeline for bipolar disorder by route of administration

Oral
Undisclosed

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for bipolar disorder by therapeutic modality

Small molecules
Undefined

According to this pipeline analysis report, the majority of the molecules that are currently in the drug development pipeline for bipolar disorder are being developed as small molecules. These molecules are chemically manufactured active substances that enter cells easily due to their low molecular weight of less than 900 Daltons.

Key questions answered in the report include

What are the drug development molecules in the various development stages of bipolar disorder?
What are the companies that are currently involved in the development of bipolar disorder for bipolar disorder?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.

mania-of-football.com is ranked #2016 in JP with 1.73M Traffic. Categories: . Learn more about website traffic, market share, and more!

Learn more about the Saphris Asenapine Market Report by Market Research Intellect, which stood at 450 million USD in 2024 and is forecast to expand to 750 million USD by 2033, growing at a CAGR of 6.5%.Discover how new strategies, rising investments, and top players are shaping the future.

Discover Market Research Intellect's Saphris Asenapine Market Report, worth 750 million USD in 2024 and projected to hit 1.2 billion USD by 2033, registering a CAGR of 6.5% between 2026 and 2033.Gain in-depth knowledge of emerging trends, growth drivers, and leading companies.

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM. Cariprazine is a D3-preferring D3/D2 receptor partial agonist under development for the treatment of schizophrenia, bipolar mania, and major depressive disorder by Hungary-based Gedeon Richter and Forest. While maintaining highest affinity for D3 receptors, cariprazine also has low potency at 5-HT2C, H1, and adrenergic receptor sites. Read More

Fatturato per gli ultimi anni, elenco utili/perdita, costo dipendenti, soci esponenti e contatti per JERSEY MANIA MARKET DI TALLAL OUALID in Robecco d'Oglio (CR)

Credit report of Company Moto-mania Shpk contains unique and detailed export import market intelligence with it's phone, email, Linkedin and details of each import and export shipment like product, quantity, price, buyer, supplier names, country and date of shipment.

Ovaj skup podataka uključuje finansijske izvještaje, račune i blokade, te nekretnine. Podaci uključuju prihode, rashode, dobit, imovinu, obaveze i informacije o nekretninama u vlasništvu kompanije. Finansijski podaci, finansijski sažetak, sažetak kompanije, preduzetnik, zanatlija, udruženje, poslovni subjekti.